Colombia vs Georgia: Average cost of multi drug-resistant tuberculosis treatment
Colombia
1,528 constant 2022 US$
in 2024
Georgia
1,600 constant 2022 US$
in 2022
Colombia rank
32nd
Georgia rank
30th
Average cost of multi drug-resistant tuberculosis treatment over time
- Colombia
- Georgia
How they compare
Georgia currently reports 1,600 constant 2022 US$ against 1,528 constant 2022 US$ in Colombia, a difference of 72 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2018 it was Colombia ahead.
Colombia ranks 32nd and Georgia ranks 30th of 92 countries.
Georgia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Colombia | Georgia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,500 constant 2022 US$ | 2,808 constant 2022 US$ | 308.5 constant 2022 US$ | Georgia |
| 2020s | 860.67 constant 2022 US$ | 2,096 constant 2022 US$ | 1,236 constant 2022 US$ | Georgia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Colombia or Georgia?
- Georgia, at 1,600 constant 2022 US$ against 1,528 constant 2022 US$ in Colombia as of 2022.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Colombia and Georgia?
- 72 constant 2022 US$, with Georgia ahead.
- How many years of comparable data are there for Colombia and Georgia?
- 5 years are reported by both, from 2018 to 2022.
- How do Colombia and Georgia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Colombia ranks 32nd and Georgia ranks 30th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.